Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May:130 Suppl 1:S47-S51.
doi: 10.1016/j.ijid.2023.03.035. Epub 2023 Mar 23.

Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?

Affiliations
Review

Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?

Sasha E Larsen et al. Int J Infect Dis. 2023 May.

Abstract

Objectives: Despite concerted efforts, Mycobacterium tuberculosis (M.tb), the pathogen that causes tuberculosis (TB), continues to be a burden on global health, regaining its dubious distinction in 2022 as the world's biggest infectious killer with global COVID-19 deaths steadily declining. The complex nature of M.tb, coupled with different pathogenic stages, has highlighted the need for the development of novel immunization approaches to combat this ancient infectious agent. Intensive efforts over the last couple of decades have identified alternative approaches to improve upon traditional vaccines that are based on killed pathogens, live attenuated agents, or subunit recombinant antigens formulated with adjuvants. Massive funding and rapid advances in RNA-based vaccines for immunization have recently transformed the possibility of protecting global populations from viral pathogens, such as SARS-CoV-2. Similar efforts to combat bacterial pathogens such as M.tb have been significantly slower to implement.

Methods: In this review, we discuss the application of a novel replicating RNA (repRNA)-based vaccine formulated and delivered in nanostructured lipids.

Results: Our preclinical data are the first to report that RNA platforms are a viable system for TB vaccines and should be pursued with high-priority M.tb antigens containing cluster of differentiation (CD4+) and CD8+ T-cell epitopes.

Conclusion: This RNA vaccine shows promise for use against intracellular bacteria such as M.tb as demonstrated by the feasibility of construction, enhanced induction of cell-mediated and humoral immune responses, and improved bacterial burden outcomes in in vivo aerosol-challenged preclinical TB models.

Keywords: Immunity; RNA vaccine; Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
repRNA product description. Development of Venezuelan equine encephalitis virus-based repRNA vaccine encoding M.tb antigens of interest delivered by a LION. LION, lipid inorganic nanoparticle; M.tb, Mycobacterium tuberculosis; repRNA, replicating RNA.

References

    1. World Health Organization. Global TB report 2022. Geneva: World Health Organization, 2022.
    1. Our World in Data. Daily confirmed COVID-19 deaths by world region, https://ourworldindata.org/grapher/daily-covid-deaths-region; 2023 [accessed 19 January 2023].
    1. Harris RC, Sumner T, Knight GM, White RG. Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. Hum Vaccin Immunother. 2016;12:2813–2832. doi: 10.1080/21645515.2016.1205769. - DOI - PMC - PubMed
    1. White RG, Hanekom WA, Vekemans J, Harris RC. The way forward for tuberculosis vaccines. Lancet Respir Med. 2019;7:204–206. doi: 10.1016/S2213-2600(19)30040-2. - DOI - PubMed
    1. Harris RC, Sumner T, Knight GM, Zhang H, White RG. Potential impact of tuberculosis vaccines in China, South Africa, and India. Sci Transl Med. 2020;12 doi: 10.1126/scitranslmed.aax4607. - DOI - PubMed